“Biosimilar products play a critical role in our corporate strategy,” Coherus BioSciences underlined as it revealed its latest filing plans for a pair of partnered biosimilar candidates: Bioeq’s FYB201 Lucentis (ranibizumab) and Innovent Biologics’ IBI305 Avastin (bevacizumab) products.
Coherus Confirms Filing Plans For Ranibizumab And Bevacizumab
Both Biosimilar Filings Have Experienced Delays
Coherus BioSciences aims to have four biosimilars on the market by 2023, including ranibizumab and bevacizumab for which it has provided updated timelines for planned US Food and Drug Administration filings.
More from Biosimilars
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.